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A screening carried out by NCI (Bethesda, USA) on compounds available in our laboratory,in order to 
ascertain their antiproliferative activity against a panel of 60 human tumor cell lines, allowed to discovery 
the 3,4-diphenylisoxazolo[3,4-d]pyridazin-7(6H)-one 1a [1] as an hit compound, often showing GI50values 
at sub-micromolar level. We synthesized some analogs of 1a, i.e.1b-gand other derivatives in which the 
NHgroup is variably alkylated, with the aim to obtain more active compounds as well as to perform 
structure-activity relationship(SAR) studies. 
 
We obtained a quite active antiproliferative compound, the 3,4-di-p-tolylisoxazolo[3,4-d]pyridazin-7(6H)-
one 1d, and verified the importance for the antiproliferative activity of the aril, and not alkyl, groups linked 
to the isoxazolo-pyridazinone moiety. Studies performed on the cell cycle progression and on some cellular 
target (ATM, procaspase-2 proteins and H2AX histone) demonstrated that 1d produces an increase of the 
cell population in pre-G0/G1 and induces cellular death by apoptosis, damaging the DNA by double strand 
breaks. UV-vis titration and viscosity measurement showed that the compound is able to give an interaction 
with the B-DNA. 
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